Malassezia in Inflammatory Bowel Disease: Accomplice of Evoking Tumorigenesis
- PMID: 35309351
- PMCID: PMC8931276
- DOI: 10.3389/fimmu.2022.846469
Malassezia in Inflammatory Bowel Disease: Accomplice of Evoking Tumorigenesis
Abstract
Accumulating evidence indicates that patients with inflammatory bowel disease (IBD) have a significantly higher risk of developing different cancers, while the exact mechanism involved is not yet fully understood. Malassezia is a lipid-dependent opportunistic yeast, which colonizes on mammalian skin and internal organs. Also, dysbiosis in fungal communities accompanied by high level of Malassezia are fairly common in inflammatory diseases such as IBD and various cancers. In cancer patients, higher levels of Malassezia are associated with worse prognosis. Once it is ablated in tumor-bearing mice, their prognostic conditions will be improved. Moreover, Malassezia manifests multiple proinflammatory biological properties, such as destruction of epithelial barrier, enrichment of inflammatory factors, and degradation of extracellular matrix (ECM), all of which have been reported to contribute to tumor initiation and malignant progression. Based on these facts, we hypothesize that high levels of Malassezia together with mycobiome dysbiosis in patients with IBD, would aggravate the microecological imbalance, worsen the inflammatory response, and further promote tumorigenesis and deterioration. Herein, we will discuss the detrimental properties of Malassezia and explore the key role of this fungus in the correlation between IBD and cancer, in order to take early surveillance and intervention to minimize the cancer risk in individuals with IBD.
Keywords: Malassezia; cancer; fungus; inflammation; inflammatory bowel disease.
Copyright © 2022 Yang, Ouyang, Pi, Feng and Yang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
Similar articles
-
Dysbiosis of skin mycobiome in atopic dermatitis.Mycoses. 2022 Mar;65(3):285-293. doi: 10.1111/myc.13402. Epub 2021 Dec 3. Mycoses. 2022. PMID: 34817898 Review.
-
Analysis of Salivary Mycobiome in a Cohort of Oral Squamous Cell Carcinoma Patients From Sudan Identifies Higher Salivary Carriage of Malassezia as an Independent and Favorable Predictor of Overall Survival.Front Cell Infect Microbiol. 2021 Oct 12;11:673465. doi: 10.3389/fcimb.2021.673465. eCollection 2021. Front Cell Infect Microbiol. 2021. PMID: 34712619 Free PMC article.
-
Malassezia species dysbiosis in natural and allergen-induced atopic dermatitis in dogs.Med Mycol. 2020 Aug 1;58(6):756-765. doi: 10.1093/mmy/myz118. Med Mycol. 2020. PMID: 31782778
-
Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common ground hypothesis.J Biomed Sci. 2018 Nov 9;25(1):79. doi: 10.1186/s12929-018-0483-8. J Biomed Sci. 2018. PMID: 30413188 Free PMC article. Review.
-
Complement and Fungal Dysbiosis as Prognostic Markers and Potential Targets in PDAC Treatment.Curr Oncol. 2022 Dec 14;29(12):9833-9854. doi: 10.3390/curroncol29120773. Curr Oncol. 2022. PMID: 36547187 Free PMC article. Review.
Cited by
-
Identification of Malassezia globosa as a Gastric Fungus Associated with PD-L1 Expression and Overall Survival of Patients with Gastric Cancer.J Immunol Res. 2022 Nov 9;2022:2430759. doi: 10.1155/2022/2430759. eCollection 2022. J Immunol Res. 2022. PMID: 36405009 Free PMC article.
-
Soluble Human Lectins at the Host-Microbe Interface.Annu Rev Biochem. 2024 Aug;93(1):565-601. doi: 10.1146/annurev-biochem-062917-012322. Epub 2024 Jul 2. Annu Rev Biochem. 2024. PMID: 38640018 Review.
-
Beyond bacteria: Role of non-bacterial gut microbiota species in inflammatory bowel disease and colorectal cancer progression.World J Gastroenterol. 2024 Sep 28;30(36):4078-4082. doi: 10.3748/wjg.v30.i36.4078. World J Gastroenterol. 2024. PMID: 39351246 Free PMC article.
-
Influence of tumor mycobiome on cancer pathogenesis (Review).Oncol Lett. 2023 Nov 2;26(6):541. doi: 10.3892/ol.2023.14128. eCollection 2023 Dec. Oncol Lett. 2023. PMID: 38020300 Free PMC article. Review.
-
Gut mycobiome dysbiosis contributes to the development of hypertension and its response to immunoglobulin light chains.Front Immunol. 2022 Dec 29;13:1089295. doi: 10.3389/fimmu.2022.1089295. eCollection 2022. Front Immunol. 2022. PMID: 36643913 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources